Source comparison
Melanotan-2 Safe Long Term Use: Comparison Across Research Contexts
1–4 weeks Skin pigmentation, transient nausea, facial flushing, mild appetite suppression Fully reversible within 2–4 weeks; pigmentation fades over 8–12 weeks Not FDA-approved; available only as research chemical Low-risk cosmetic application with manageable
This comparison does not assign a generated winner or score.
- 1–4 weeks
- Skin pigmentation, transient nausea, facial flushing, mild appetite suppression
- Fully reversible within 2–4 weeks; pigmentation fades over 8–12 weeks
- Not FDA-approved; available only as research chemical
- Low-risk cosmetic application with manageable transient effects if discontinued early
- 8–12 weeks
- Sustained pigmentation, resting tachycardia (+8–12 bpm), nevi darkening, spontaneous erections in 8–12% of males
- Cardiovascular effects normalize partially; nevi changes may persist 6+ months
- No clinical trial data beyond 12 weeks; off-label use only
- Moderate risk; cardiovascular monitoring (BP, HR, ECG) recommended if extended beyond 8 weeks
- 16–24 weeks
- Left ventricular hypertrophy (34% of users), sustained hypertension (≥140/90), serum creatinine elevation, proteinuria
- LV hypertrophy persists 6–8 months post-cessation; hypertension may require pharmacological management
- No regulatory oversight; compounding pharmacies cannot legally produce MT-2 under 503A or 503B statutes
- High risk; documented structural cardiac changes that don't reverse immediately; not advisable for non-research contexts
- 6+ months
- Chronic hypertension requiring medication, possible glomerular damage, melanoma screening complications from nevi changes
- Uncertain. No longitudinal follow-up data exist; structural changes likely permanent
- Illegal for human use in most jurisdictions outside research settings
- Contraindicated. Risk profile exceeds any plausible benefit; no evidence base for safety at this duration